The project aims to develop an innovative technological framework for the development of personalised chemotherapy with reduced toxicity, using ovarian carcinoma as a model, but with potential for extension to other types of tumours. In particular, we plan to develop a fully automated system for performing drug sensitivity tests on peritoneal carcinoma cells taken from patients in order to assess individual response to chemotherapy drugs. This system, designed for use in standard hospital testing laboratories, aims to provide physicians with useful information to optimise the course of treatment by identifying the most effective chemotherapy regimen for the patient under examination and highlighting genetic variants associated with possible chemoresistance
Project co-financed by the Regional Operational Programme (ROP) ERDF 2014-2020 "Investments for growth and employment" - Activity 1.3.b - DGR no. 1489/2017. Eligible expenditure: 403,398.00 €. Grant awarded: € 260,726.22 Co-financing rate 64.6%. Total eligible project expenditure: €1.185.420,00 - Total funded project contribution: € 862.037,00. Operation start date 05/11/2018. Operation end date 05/02/2022 (updated data).